Neurophyxia
s-Hertogenbosch, NL · 1 known investors
Neurophyxia is developing a neuroprotectant compound (2-iminobiotin) for treating brain injury and tissue damage caused by stroke, cardiac arrest, and birth asphyxia. The compound is in Phase IIb/III clinical development.
Investors · 1
Frequently asked questions
- What does Neurophyxia do?
- Neurophyxia is developing a neuroprotectant compound (2-iminobiotin) for treating brain injury and tissue damage caused by stroke, cardiac arrest, and birth asphyxia. The compound is in Phase IIb/III clinical development.
- Who are Neurophyxia's investors?
- Neurophyxia's investors include Waterman Ventures.
- Where is Neurophyxia headquartered?
- Neurophyxia is headquartered in s-Hertogenbosch, NL.